Last reviewed · How we verify
DMTS
At a glance
| Generic name | DMTS |
|---|---|
| Also known as | DMTS |
| Sponsor | Teikoku Pharma USA, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis (PHASE4)
- A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis
- The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study (NA)
- A Real-world Study of Disease-modifying Therapy Treatment Outcomes in Patients With Spinal Muscular Atrophy
- Effects of Ocrevus in Relapsing Multiple Sclerosis (PHASE4)
- Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type (PHASE2)
- Evaluation of the Dexmedetomidine Transdermal Systems for Postoperative Analgesia Following Abdominoplasty (PHASE2)
- Libyan Multiple Sclerosis Registry Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |